In this study, we found that treatment with mTOR inhibitors did not reduce the risk of de novo cancer development in kidney transplantation patients, a result that contradicts that of previous studies (Ekberg et al., 2007; Kasiske et al., 2004). The gene discussed is MTOR; the disease is cancer.